1. Clinical Overview
A fixed-dose combination ophthalmic suspension containing a site-specific soft corticosteroid (Loteprednol etabonate) and a broad-spectrum aminoglycoside antibiotic (Tobramycin). It is designed for the treatment of steroid-responsive inflammatory ocular conditions where the risk of superficial bacterial infection is high or where there is an existing bacterial infection. Loteprednol etabonate is a 'soft drug' engineered to undergo rapid hydrolysis to inactive metabolites after exerting its therapeutic effect, thereby minimizing systemic side effects. Tobramycin provides bactericidal coverage against a wide range of Gram-negative and some Gram-positive ocular pathogens.
| Onset | Duration | Bioavailability |
|---|---|---|
| Anti-inflammatory effect: Within hours. Antimicrobial effect: Bactericidal action begins upon contact. | Topical ocular effect lasts approximately 4-6 hours per instillation, necessitating multiple daily doses. | Negligible systemic bioavailability following topical ocular administration (<1%). |
2. Mechanism of Action
Loteprednol etabonate binds to glucocorticoid receptors in ocular tissues, leading to the induction of phospholipase A2 inhibitory proteins (lipocortins). This inhibition blocks the release of arachidonic acid from membrane phospholipids, thereby preventing the synthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Tobramycin is a bactericidal aminoglycoside that binds irreversibly to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing misreading of the genetic code.
3. Indications & Uses
- Steroid-responsive inflammatory ocular conditions with a risk of or existing superficial bacterial infection.
- Post-operative inflammation following ocular surgery (e.g., cataract surgery) where prophylactic antibiotic coverage is desired.
- Blepharitis and conjunctivitis where significant inflammation and bacterial infection coexist.
4. Dosage & Administration
Adult Dosage: One drop instilled into the affected eye(s) 4 times daily. In severe inflammation, dosing may be initiated at one drop every 1-2 hours during waking hours, then tapered. Do not discontinue abruptly; taper frequency.
Administration: 1. Wash hands. 2. Shake the suspension well before use. 3. Tilt head back, pull lower eyelid down to form a pouch. 4. Instill one drop without touching the dropper tip to eye or any surface. 5. Close eyes gently for 1-2 minutes, applying gentle pressure to the nasolacrimal duct (inner corner of eye) to minimize systemic absorption. 6. Wait at least 5-10 minutes before instilling any other ophthalmic medication.
5. Side Effects
Common side effects may include:
- Transient ocular burning or stinging upon instillation
- Blurred vision immediately after instillation
- Foreign body sensation
- Itching
- Mild conjunctival hyperemia
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other topical ophthalmic NSAIDs (e.g., Ketorolac, Nepafenac) | Increased risk of corneal healing impairment and potential for corneal melt/perforation. | Major |
| Systemic or other topical corticosteroids | Additive risk of elevated IOP, cataract, and systemic corticosteroid side effects. | Moderate |
| Other aminoglycosides (topical or systemic) | Additive risk of ototoxicity and nephrotoxicity (though low with topical use, caution in patients with renal impairment). | Moderate |
| Neuromuscular blocking agents (e.g., Succinylcholine, Atracurium) | Tobramycin may potentiate neuromuscular blockade, leading to respiratory depression. | Major (for systemic tobramycin; theoretical risk with topical). |
| Loop diuretics (e.g., Furosemide) | Increased risk of ototoxicity and nephrotoxicity with systemic aminoglycosides. | Moderate (theoretical risk with topical). |
7. Patient Counselling
- DO shake the bottle well before each use.
- DO wash your hands before and after use.
- DO apply gentle pressure on the inner corner of the eye (nasolacrimal duct) for 1-2 minutes after instillation.
- DO wait at least 5-10 minutes before using any other eye drops.
- DO NOT touch the dropper tip to your eye, fingers, or any surface.
- DO NOT wear contact lenses while using this medication or if you have an active infection/inflammation.
- DO NOT share your eye drops with others.
- DO NOT stop using the medication abruptly without consulting your doctor; a taper may be needed.
8. Toxicology & Storage
Overdose: Topical overdose is unlikely to cause acute systemic toxicity. Symptoms may include severe ocular irritation, pain, increased redness, corneal edema, and worsening of glaucoma. Accidental oral ingestion may lead to symptoms of systemic corticosteroid and aminoglycoside overdose (e.g., GI upset, electrolyte imbalance, ototoxicity, nephrotoxicity).
Storage: Store at controlled room temperature (15°C to 25°C). Protect from light and moisture. Do not freeze. Keep the bottle tightly closed when not in use. Discard the bottle 4 weeks after opening to prevent contamination. Keep out of reach and sight of children.